Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
This study was designed to evaluate if patients with hypertension treated early with a combination therapy would achieve better blood pressure (BP) control, than patients being treated with a classical sequential add-on therapy.
The study compared the effects of the two treatment strategies: Treatment initiation on a single compound, either with aliskiren or amlodipine, and then continuation with the combination of both versus treatment initiation with the combination of aliskiren/amlodipine and then continuation with the combination. The study also evaluated if the overall mean sitting systolic blood pressure (msSBP)-lowering effect during the study, as well as the change from baseline to study end in msSBP, are superior in the group having received combination therapy from the beginning.
The study further evaluated the BP-lowering efficacy and tolerability of both treatment strategies.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female outpatients ≥ 18 years of age
Participants with essential hypertension:
* Naive participants must have a mean sitting Systolic Blood Pressure (msSBP) ≥ 150 mmHg and \< 180 mmHg at Visit 1 and Visit 2. (Participants are considered 'naïve' if they have never been treated with any antihypertensive medication.)
* All participants must have a msSBP ≥ 150 mmHg and \< 180 mmHg at Visit 2
Written informed consent to participate in this study prior to any study procedures
You may not be if
Severe hypertension
Pregnant or nursing (lactating) women
Pre-menopausal women not taking accepted form of birth control
Serum potassium ≥ 5.5 mEq/L (mmol/L) at Visit 1
History of cardiovascular conditions
Uncontrolled Type 1 or Type 2 diabetes mellitus
Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with similar chemical structures